Euronext Paris

New Medidata Technology Helps Sponsors and CROs Improve Diversity and Inclusion in Clinical Trials

Retrieved on: 
Thursday, October 13, 2022
Health, FDA, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Cros, SIMULIA, CATIA, Dassault Group, Patient, 3D, DELMIA, Euronext Paris, Research, Â, Forecasting, SOLIDWORKS, African Americans, Sex, Goal, Diversity, Learning, Industry, FDA, Legislation, Benchmarking, Pharmaceutical industry, GEOVIA, ENOVIA, Medidata Solutions, Compass, BIOVIA

Medidata , a Dassault Systmes company, has launched the Intelligent Trials Diversity Module to help improve the equity of clinical trials by providing site-level participant demographic data including race, sex, age, and ethnicity.

Key Points: 
  • Medidata , a Dassault Systmes company, has launched the Intelligent Trials Diversity Module to help improve the equity of clinical trials by providing site-level participant demographic data including race, sex, age, and ethnicity.
  • The new Intelligent Trials Diversity Module will help sponsors and clinical research organizations (CROs) benchmark the diversity of their trials and identify sites that are more successful at enrolling diverse patients.
  • Historically, clinical trials have been shown to recruit disproportionately white participants, which raises concerns about the generalizability of trial results to underrepresented patients.
  • With the addition of the Diversity Module, sponsors and CROs can set goals by benchmarking diversity at the study level in the same indication.

SeeHer and Ipsos Release Strive for More Whitepaper That Showcases How Positive Depictions of Females in Advertising Can Lead to Superior Business Outcomes

Retrieved on: 
Thursday, October 13, 2022
Marketing, Advertising, Communications, Consumer, Technology, Women, Telecommunications, Quotient, Advertising, Movement, Female, Association of National Advertisers, EVP, Woman, Organization, ANA, Mother, Patient, Gender equality, Euronext Paris, Research, Multimedia, Music, Partnership, SRD, Ipsos, Insight, ISIN, Goal, Sport, Marketing, SBF, 120, Association, GEM, Social media, FP, Database, Reuters, Solution, Toy, Practice of law

View the full release here: https://www.businesswire.com/news/home/20221013005155/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221013005155/en/
    For the whitepaper, SeeHer and Ipsos sought to better understand the impact of creative and thematic elements used in ads depicting women.
  • They also used performance metrics, such as brand choice intent and long-term brand relationship, to evaluate the benefits of positive female representation on brands.
  • Key findings from the whitepaper include:
    Positive female representation: Elevated portrayals of women are significantly more likely to drive positive business results.
  • Ipsos has demonstrated that the positive portrayal of women and girls, as measured by GEM, is significantly predictive of in-market success of advertising.

SCIENTIFIC GAMES AND GROUPE FDJ DEBUT LOTTERY GAMES OF THE FUTURE

Retrieved on: 
Wednesday, October 12, 2022
International, EN, STOXX, Euronext, VP/CSS, Compartment, Technology, All rights reserved, Science, LLC, FDJ, Euronext Paris, QR, Multimedia, Senior, Industry, SBF, 120, Scientific Games, Digital, View, Online gambling, Video game console

ATLANTA , Oct. 12, 2022 /PRNewswire/ -- Scientific Games and Groupe FDJ, the operator of France's national lottery La Franϛaise des Jeux, unveiled iDecide, a revolutionary lottery game enhancement that gives instant scratch card players the option to continue their play experience with a digital game and potentially expand their winnings. The concept is a first for the global lottery industry.

Key Points: 
  • The debut of iDecide comes days before the World Lottery Summit in Vancouver, where demonstrations will be hosted by Groupe FDJ and Scientific Games, partners on the innovation.
  • Jeff Martineck, Senior VP of Global Lottery Product Innovation for Scientific Games, said,"Games featuring iDecide modernize the lottery experience for the consumer.
  • Best of all, iDecide games firmly connect lottery retailers to the digital channel, maximizing revenues and contributions to lottery good cause programs."
  • Scientific Games is a leading provider of lottery products, technology and services to government-sponsored lottery programs globally.

Thales Encryption Key Management Innovations Help Organizations Achieve Digital Sovereignty Across Hybrid and Multi-Cloud Environments

Retrieved on: 
Wednesday, October 12, 2022
Software, Mobile, Wireless, Networks, Professional Services, Internet, Business, Data Management, Apps, Applications, Technology, Security, Online Privacy, Other Professional Services, Other Technology, Cloud, BYOK, Risk, Risk assessment, VP, Society, HO, Organization, Euronext Paris, Google, Multimedia, Microsoft, Partnership, Artificial intelligence, AWS, Drive, Industry, Salesforce, Google Cloud, Oracle Cloud, SAP, Group, CipherTrust, Microsoft Azure, Amazon Web Services, Azure, Solution, Compliance, Video game console, Computer data storage, Weapon, Thales of Miletus, Gmail, Calendar

Thales today announced the latest innovations of CipherTrust Cloud Key Manager that help organizations address digital sovereignty requirements across major public clouds including Amazon Web Services, Google Cloud, Microsoft Azure, Oracle Cloud, SAP and Salesforce.

Key Points: 
  • Thales today announced the latest innovations of CipherTrust Cloud Key Manager that help organizations address digital sovereignty requirements across major public clouds including Amazon Web Services, Google Cloud, Microsoft Azure, Oracle Cloud, SAP and Salesforce.
  • Organisations that leverage these cloud providers can now leverage CipherTrust Cloud Key Managers Bring Your Own Key (BYOK) capabilities for enhanced data security and encryption key ownership.
  • With BYOK functionality, customers can centralise key management across all clouds with external key management services ensuring full encryption capabilities and key lifecycle management to maintain control of sensitive data across multiple public clouds.
  • CipherTrust Cloud Key Manager, the industry-leading multi-cloud encryption key lifecycle management solution, enables customers to migrate to the cloud and manage both native cloud keys as well as Bring Your Own Keys (BYOK).

Eutelsat Strategy Update on the Proposed Combination with OneWeb

Retrieved on: 
Wednesday, October 12, 2022
Technology, Satellite, Mobile, Wireless, Audio, Video, Telecommunications, Networks, Efficiency, Rationalization, Euronext Paris, Publication, CEO, Aviation, LEO, Adoption, AMF, Communication, IOT, Achievement, Acceleration, THE, Radio-frequency identification, Knowledge, OR, Industry, BST, Maintenance, Government, Connectivity, Aviation and Maritime Investigation Authority, Satellite, Time, Risk, Growth, Woman, Consumer Broadband and Digital Television Promotion Act, CAGR, Research, Multimedia, ETL, FY, GEO, EBITDA, Mobile broadband, Compliance, INTO, Capital expenditure, Man, Partnership, US, Digital divide, DTH, Communications satellite, Risk management, Renewable energy, Online shopping, Fine chemical, Audit, Cryptocurrency, Pharmaceutical industry, Eutelsat, OPEX, Mobility, OneWeb

View the full release here: https://www.businesswire.com/news/home/20221011006201/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221011006201/en/
    Eutelsat Communications (Euronext Paris: ETL) today host a Strategic Update on the proposed combination with OneWeb, announced in July 2022.
  • Eutelsat and key OneWeb shareholders signed a Memorandum of Understanding in July 2022, with a view to combining Eutelsat and OneWeb in an all-share transaction, whereby Eutelsat and OneWeb shareholders will each hold 50% of the Eutelsat shares2.
  • Following completion of the combination, Eutelsat and OneWeb will begin working together on the design of OneWebs future Gen 2 constellation.
  • Eva Berneke, CEO of Eutelsat, and Neil Masterson, CEO of OneWeb, said: The proposed combination between Eutelsat and OneWeb represents a decisive leap forward for Satellite Connectivity.

Poxel to Present DESTINY-1 Phase 2 Results for PXL065 in NASH at AASLD The Liver Meeting® 2022

Retrieved on: 
Wednesday, October 12, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, ACSL4, Non-alcoholic fatty liver disease, Pioglitazone, Euronext Paris, ADPKD, Liver cancer, American Association, Association, Adrenoleukodystrophy, Biomarker, Adenosine, American Association for the Study of Liver Diseases, QD, Lists of diseases, Fibrosis, Inflammation, Company, Obesity, Bone, Degenerative disease, Cirrhosis, European Association for the Study of the Liver, ALD, Liver failure, FDA, Time, Risk, Deuterium, EASL, Edema, Weight gain, AASLD, Type 2 diabetes, Disease, Triglyceride, Cholesterol, Histology, Partnership, Human, National Disaster Management Authority (India), AMPK, Safety, MPC, Forward-looking statement, Fatty liver disease, Institute of Liver and Biliary Sciences, Pharmaceutical industry, Medical imaging, Copper, Euronext, Liver, Imeglimin, Patient

The study also assessed the effects of PXL065 on liver histology and other metabolic and non-metabolic biomarkers.

Key Points: 
  • The study also assessed the effects of PXL065 on liver histology and other metabolic and non-metabolic biomarkers.
  • Analysis of histologic changes was based on paired liver biopsies in PXL065 vs. placebo-treated NASH patients before and after the 36-week treatment period.
  • Across all PXL065 treatment arms (pooled data), 39% of patients had fibrosis improvement by 1 stage without worsening NASH (%) vs. 17% with placebo.
  • For the treatment of NASH, PXL065 (deuterium-stabilized R-pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1).

Ekinops Q3 2022: +36% growth +28% for the first nine months of the year Revenue guidance raised

Retrieved on: 
Tuesday, October 11, 2022
EMEA, Growth, Acceleration, Software-defined networking, Euronext Paris, Optical Transport Network, Acquisition, Environment, EBITDA, Beauty salon, Video game, Renewable energy, Access, Software, Group, Service

Acceleration of growth in Q3 2022: +36%

Key Points: 
  • Acceleration of growth in Q3 2022: +36%
    Ekinops reported Q3 2022 consolidated revenue of 32.8 million, up by a robust +36% versus Q3 2021.
  • The first nine months were marked by strong growth in international business (+23%), with an increase inall regions, particularly North America and Asia-Pacific.
  • After virtually stable revenue in its domestic market in 2021 and Q1 2022, Ekinops restored sharp growth in France.
  • Boosted by robust sales momentum in Access solutions, Q3 2022 growth amounted to +59% in France, an increase of +39% over the first nine months.

EQS-News: Abivax: first US patient enrolled in global phase 3 program with obefazimod in ulcerative colitis

Retrieved on: 
Tuesday, October 11, 2022
Degenerative disease, EMA, IQVIA, Patient, Euronext Paris, Hepatocellular carcinoma, Twitter, Program, Gastroenterology, Cancer, Icahn School of Medicine at Mount Sinai, ISIN, Immune system, Marketing, CEO, UC, Mount Sinai, CEST, Ulcerative colitis, Inflammation, FDA, CRO, Pharmaceutical industry, Euronext, Medicine, Abivax

Obefazimod has already shown very promising results in the precedent phase 2a and phase 2b induction and maintenance trials.

Key Points: 
  • Obefazimod has already shown very promising results in the precedent phase 2a and phase 2b induction and maintenance trials.
  • As a practicing gastroenterologist, I am confronted every day with the high unmet medical need for safe therapies that have long-term efficacy and convenient administration for patients with ulcerative colitis.
  • I am optimistic that the ABTECT program will confirm obefazimods potential to address these medical needs.
  • Prof. Hartmut J. Ehrlich, M.D., CEO of Abivax, added: We are very happy that our pivotal global phase 3 program has successfully started in the US with the enrollment of the first patient.

Verimatrix Recognized as a Sample Vendor in 2022 Gartner® Hype Cycle™ for Application Security

Retrieved on: 
Tuesday, October 11, 2022
Apps, Applications, Technology, Security, Other Technology, Professional Services, Software, Internet, Data Management, Web3, Other Professional Services, API, Software as a service, Hype cycle, Euronext Paris, Research, Publication, CISO-FM, Collection, Technology, Software, Industry, PII, Application, IP, Fraud, Compliance, Leadership, Online shopping, Gartner, Verimatrix

Verimatrix, (Euronext Paris: VMX) (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced it has been identified as a Sample Vendor in the application shielding category of the Gartner Hype Cycle for Application Security 2022 report.

Key Points: 
  • Verimatrix, (Euronext Paris: VMX) (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced it has been identified as a Sample Vendor in the application shielding category of the Gartner Hype Cycle for Application Security 2022 report.
  • In certain industries, such as financial services and online retail, it can also be used to improve the user experience.
  • Verimatrix XTD Enterprise threat detection via mobile apps, APIs and unmanaged devices to aid in compliance and security incident management through the collection and analysis of security events
    Gartner, "Hype Cycle for Application Security, 2022," Joerg Fritsch, 11 July 2022.
  • Gartner and Hype Cycle are registered trademarks of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission.

AB Science receives first agencies authorizations to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s disease

Retrieved on: 
Monday, October 10, 2022
Medicine, Mini–Mental State Examination, Euronext Paris, Scientific Committee on Antarctic Research, Science, INT, ADAS, Lists of diseases, Sorbonne University, AMF, Population, Donanemab, ALS, Company, MMSE, Marketing, Neurology, Veterinary medicine, Incidence, Communication, Central nervous system, Macrophage, B cell, Research, Cell, Mast cell, Memantine, Degenerative disease, Microglia, PKI, Alzheimer's disease, Ageing, AD, Survival, Inflammation, Vacuum, Memory, Cholinesterase, Disease, Multiple sclerosis, ADAS-Cog, Cognition, Patient, Amyotrophic lateral sclerosis, III, MD, Safety, AE, AB, Tyrosine kinase inhibitor, Pharmaceutical industry, Medical imaging, Vaccine, Dietary supplement, Copper, Neurodegeneration

The objective of study AB21004 is to confirm treatment effect with masitinib 4.5 mg/kg/day as an adjunct to cholinesterase inhibitor and/or memantine in patients with mild-to-moderate Alzheimer's disease.

Key Points: 
  • The objective of study AB21004 is to confirm treatment effect with masitinib 4.5 mg/kg/day as an adjunct to cholinesterase inhibitor and/or memantine in patients with mild-to-moderate Alzheimer's disease.
  • Professor Bruno Dubois, MD, principal investigator of the study and Professor of Neurology at Sorbonne University, France commented, We are very excited to initiate this confirmatory phase III study with masitinib in Alzheimers disease.
  • There is a vacuum of treatment options for patients with mild or moderate Alzheimers disease.
  • The results from first phase 2B/3 study, AB09004, were very encouraging, especially considering this is a difficult to treat patient population.